Why Good Clinical Data Still Fails to Win Coverage

One of the hardest conversations I have with medtech executives happens after a study has already succeeded.

The technology worked.

The endpoints were met.

The investigators were pleased with the results.

The manuscript is underway.

The leadership team is preparing to share the findings with investors, commercial partners, health systems, and prospective customers. From a traditional clinical perspective, the study did exactly what it was designed to do.

Then commercialization begins. Adoption is slower than expected. Hospitals ask for information that was never collected.Payers want to understand comparative value, resource utilization, patient selection, and real-world impact.

Value analysis committees ask what implementation will require from staff, whether the technology fits into existing workflows, and how it compares with what the organization is already using.

Physicians may appreciate the clinical results but remain uncertain about which patients should receive the technology, how it changes their current care pathway, or whether the benefit is meaningful enough to justify changing practice.

That is usually when the company asks a very reasonable question:

“How can we have good data and still be struggling to gain coverage or adoption?”

The answer is often uncomfortable.

The study may have been scientifically successful without generating the evidence commercial stakeholders needed to make a decision.

Clinical evidence and commercial evidence overlap, but they are not the same thing.

Clinical evidence may demonstrate that a technology is safe, effective, accurate, or clinically useful under the conditions defined by the protocol.

Commercial evidence has to do something broader. It has to help a payer determine whether coverage is justified. It has to help a health system understand whether adoption makes operational and financial sense. It has to help a provider decide whether the technology improves care enough to change an established workflow.

It has to help a value analysis committee understand what implementation will require and what measurable value the organization should expect in return.

It may also need to help investors understand whether the company has reduced the risks standing between regulatory achievement and meaningful commercial use.

Those are very different decisions.

The question is not whether the original study was good. The question is whether it was designed to support the next decision the company needed someone else to make.

That distinction is where many otherwise promising evidence programs begin to fall short.

The Evidence Investment Has Already Been Made

By the time a company realizes it has a commercial evidence gap, it has usually already invested a substantial amount of money, time, organizational attention, and credibility into the study.

• The protocol has been written and amended.
• Sites have been selected.
• Contracts and budgets have been negotiated.
• Investigators and coordinators have been trained.
• Patients have been recruited.
• Data have been collected, cleaned, analyzed, and interpreted.
• The company may have spent months or years reaching the primary endpoint.

That is why these conversations are so difficult. The company did not fail to invest in evidence. It invested heavily. The problem is that the investment may have produced a narrower asset than leadership expected.

A successful study can still leave the company unable to explain how the technology affects total cost of care, downstream utilization, provider workflow, patient burden, implementation requirements, or the existing treatment pathway.

It can demonstrate clinical performance without clarifying which patients benefit most. It can establish statistical significance without demonstrating why the difference matters to a payer or health system. It can support publication without supporting coverage.

This is what makes evidence strategy such an important commercial discipline. The value of a study is not determined only by whether it reaches its endpoint. It is also determined by how many meaningful decisions the resulting evidence can support.

A study that supports regulatory progress, publication, reimbursement planning, provider adoption, investor communication, and the design of the next evidence program is a much more valuable commercial asset than a study that supports only one of those objectives.

The goal is not to force every study to answer every possible question.

That would be unrealistic, expensive, and often scientifically inappropriate.

The goal is to understand which decisions matter next and make deliberate choices about which questions should be answered now, which should be addressed later, and how the studies should build on one another.

Without that planning, companies often discover that they completed the study they intended to run but not the evidence program they actually needed.

The Evidence Gap

Regulators, physicians, health systems, value analysis committees, payers, and investors do not evaluate a technology in the same way.

They are not trying to answer the same question.

Regulators may focus on whether the technology meets the applicable standards for safety and effectiveness.

Physicians may focus on clinical utility, patient selection, treatment burden, and whether the technology meaningfully improves decision making or care.

Hospital leaders may focus on staffing, throughput, implementation requirements, capital expense, training, workflow disruption, and the effect on existing service lines.

Value analysis committees may consider clinical benefit alongside operational feasibility, contracting, budget impact, supply chain implications, and the availability of alternatives.

Payers may assess medical necessity, comparative effectiveness, generalizability, durability of benefit, downstream utilization, total cost of care, and the strength of the evidence supporting coverage.

Investors may focus on whether the evidence has reduced commercial risk and made reimbursement, adoption, or the next financing milestone more achievable.

A study can answer one stakeholder’s question exceptionally well while leaving every other stakeholder to fill in the gaps. That is not necessarily a failure of scientific design. It is often a failure to define the full decision environment before the study begins.

Companies frequently assume that additional questions can be answered later.

Technically, that may be true.

Practically, many of those questions are far easier and less expensive to address while a prospective study is already underway.

If patients are already enrolled, adding a well-defined patient-reported outcome may be manageable.

If sites are already documenting care, collecting selected workflow or resource utilization measures may be feasible.

If providers are already interacting with the technology, assessing usability, implementation barriers, or changes in clinical decision making may create valuable insight.

Once the study is complete, those same questions may require another protocol, another round of site contracting, another data collection period, another statistical analysis plan, and another major investment.

Sometimes the original patient population cannot be recreated. Sometimes the sites have moved on. Sometimes the company no longer has the capital or time to run the follow-up study it now knows it needs.

That is why the evidence gap is not simply an academic issue. It is a financing issue. A reimbursement issue. A market access issue. A commercialization issue.

And in some cases, it becomes a company survival issue.

Where Companies Usually Go Wrong

Most companies do not intentionally ignore commercial evidence. The problem is that study development is often organized around the expertise already in the room. Clinical investigators, regulatory teams, biostatisticians, Medical Affairs, commercial leaders, and market access experts each bring an important perspective, but none is sufficient by itself.

The strategy begins to drift when one perspective quietly becomes the evidence plan for the entire company. A clinically strong study may lack payer-relevant outcomes, while a regulatory study may achieve its milestone without providing enough support for adoption.

Before the protocol advances, teams should ask who must act on the results, what uncertainty is preventing that action, whether the comparator reflects real practice, and whether the study will support coverage, adoption, and the next evidence investment. These questions do not replace scientific or regulatory review. They make it more strategically useful.

The Study Was Successful. The Evidence Story Was Not.

I have reviewed evidence programs with a positive primary endpoint, a credible publication strategy, and strong investigator support. On paper, the company appeared to be in an excellent position.

Yet the commercial team could not clearly explain how the technology changed the care pathway. The payer story depended on unmeasured assumptions, the hospital value proposition relied on undocumented workflow savings, and the economic model required data that had not been collected.

The study had succeeded, but the evidence had not resolved the uncertainty preventing coverage or adoption. Good data must be connected to the decision they are intended to change. Expecting each stakeholder to translate a clinical result into a commercial rationale is rarely a reliable strategy.

The Questions That Matter

Beyond safety and effectiveness, stakeholders increasingly want to understand what happens when a technology enters real clinical practice.

• Does it improve workflow or reduce staff burden?
• Does it reduce downstream testing, procedures, length of stay, or resource utilization?
• Which patients benefit most, and are the study population and sites representative of actual use?
• What implementation barriers, training, infrastructure, or process changes are required?
• How does it compare with current practice, and is the benefit meaningful enough to change behavior?

These questions often determine whether a clinical result becomes useful in the real world. A positive endpoint shows that something happened. A commercial evidence strategy explains why the result should lead to action. The right measures depend on the technology, reimbursement environment, competitive landscape, and next commercial milestone.

Clinical Success Does Not Automatically Become Commercial Success

A strong clinical result may be necessary for commercialization, but it is rarely sufficient by itself. Providers, payers, health systems, value analysis committees, and investors each evaluate the evidence through a different lens.

Every protocol decision has downstream consequences. The endpoint shapes the reimbursement story, the comparator affects payer confidence, eligibility criteria define the potential covered population, and workflow, patient-reported, or resource utilization measures may determine whether stakeholders see practical value.

This does not mean every protocol should be overloaded with commercial endpoints. It means every protocol should be reviewed for commercial consequences. Keeping a study focused is reasonable when the remaining questions are deliberately assigned to the next stage of the evidence plan.

Every Study Should Create Future Options

Most teams naturally focus on the milestone directly ahead, such as regulatory clearance, enrollment completion, publication, or a reimbursement discussion. Those objectives matter, but every prospective study should also reduce uncertainty around the company’s next investment.

That may mean collecting selected resource utilization data, patient-reported outcomes, workflow measures, implementation insights, or operational lessons that strengthen future payer discussions and study design.

The goal is not simply to create more data. It is to create more options. A strong evidence program makes the next decision easier, reduces the assumptions carried forward, and helps leadership understand what has been proven, what remains uncertain, and which evidence will create the greatest value next. Each study should strengthen the one that follows.

What Most Leadership Teams Do Not Realize

The problem is often not that the organization needs more evidence. It needs the right evidence, in the right sequence, for the right audience.

That realization moves the discussion beyond protocol language to the decisions the company must support: which stakeholder matters next, what uncertainty is preventing action, what can be captured efficiently now, and which questions require a separate study.

A strategic CRO should do more than execute the protocol it receives. Execution, monitoring, data quality, and timelines remain essential, but flawless execution of the wrong study will not produce the outcome the company needs. The strategic work begins by confirming that the planned evidence supports the company’s actual business objectives and fits into a larger commercialization plan.

What Companies Realize Too Late

The most frustrating evidence gaps are often the ones that would have been relatively easy to address before enrollment began.

A company completes a study and realizes it should have documented the number of avoided procedures.

It recognizes that provider workflow was central to the value proposition but never measured.

It discovers that the patient subgroup most likely to benefit was not prespecified or adequately represented.

It begins payer discussions and learns that the comparator does not reflect the real-world decision.

It develops an economic model and finds that the necessary utilization inputs are unavailable.

It starts preparing for health system adoption and realizes implementation requirements were never formally assessed.

At that point, the company has several choices, and none is especially attractive.

It can proceed with an evidence story built partly on assumptions.

It can rely on retrospective analyses that may be less persuasive or less complete.

It can conduct another study.

Or it can delay the commercial objective until stronger evidence is available.

All of those options cost something.

Money.

Time.

Credibility.

Negotiating leverage.

Investor confidence.

Commercial momentum.

This is why commercialization planning should begin before protocol finalization.

Not because every future need can be predicted perfectly.

It cannot.

But the major stakeholder questions are often knowable.

The coverage pathway can be assessed.

The likely adoption barriers can be explored.

The competitive and comparator landscape can be reviewed.

The future economic evidence requirements can be anticipated.

The company can define what decisions the current study should support and what decisions will require later evidence.

The strongest evidence strategies do not eliminate uncertainty.

They reduce it deliberately.

Why This Matters Now

Today’s medtech companies are operating under intense pressure.

Capital is more selective.

Investors expect research dollars to be deployed efficiently.

Payers continue to raise evidence expectations.

Health systems scrutinize new technology decisions more carefully.

Clinical teams are asked to do more with limited infrastructure.

Commercial timelines remain aggressive.

Every evidence investment has to work harder.

Companies can no longer afford to treat regulatory, clinical, reimbursement, market access, and commercialization strategies as separate activities that will eventually come together on their own.

They have to be connected early enough for the evidence plan to reflect them.

That does not mean every study needs to become larger, longer, or more complicated.

Often, the opposite is true.

A thoughtful evidence strategy can help a company avoid unnecessary endpoints, poorly chosen comparators, uninformative data collection, or studies that duplicate what is already known.

The objective is not maximal data collection.

It is maximal strategic value from the evidence being generated.

The companies that manage this well are not necessarily the ones with the largest budgets.

They are the ones that understand what each study is supposed to accomplish and how it prepares the organization for the next decision.

They know which questions belong in the current protocol.

They know which questions should be deferred.

They know which stakeholder must be convinced next.

And they know that a study is not commercially valuable simply because it produces a positive result.

It is commercially valuable when it reduces the uncertainty that stands between the technology and meaningful use.

TTi’s Perspective

At TTi, we do not believe clinical teams, founders, regulatory experts, investigators, or Medical Affairs professionals should have less influence over study development.

Quite the opposite.

Each brings a perspective the evidence program needs.

Founders and leadership teams bring the company’s vision and strategic priorities.

Clinical investigators bring expertise in patient care, disease progression, clinical relevance, and feasibility.

Medical Affairs brings scientific insight and an understanding of the clinical community.

Regulatory teams bring critical knowledge of the applicable regulatory pathway and evidence requirements.

Biostatisticians bring rigor to the design, analysis, and interpretation of the study.

Market access and reimbursement experts bring an understanding of coverage, coding, payment, payer expectations, and the evidence needed to support value.

What our team adds is an integrated commercialization lens.

We help companies pressure-test whether the study they are planning is actually the study they need.

That includes reviewing who the evidence must convince, what decision it should support, how the comparator aligns with real practice, whether the planned outcomes are meaningful to commercial stakeholders, and how the study fits into the larger evidence sequence.

Sometimes that means changing an endpoint.

Sometimes it means refining comparator strategy.

Sometimes it means adding pragmatic elements, real-world outcomes, workflow measures, healthcare resource utilization, patient-reported outcomes, or implementation data.

Sometimes it means reconsidering the population, sites, follow-up period, or operational model.

Sometimes it means recognizing that a question belongs in a future study rather than forcing too much into the current one.

Most studies are not scientifically poor.

They are simply designed around a narrower question than the company’s commercial future requires.

The goal is not simply to complete a successful study.

The goal is to generate evidence that changes decisions.

Remember:

Evidence is only valuable if it changes the next decision.

– Dr. April